The Role of Toll-Like Receptor 4 in Infectious and Noninfectious Inflammation

Monica Molteni, Sabrina Gemma, and Carlo Rossetti

Dipartimento di Biotecnologie e Scienze della Vita, Università degli Studi dell’Insubria, Via J. H. Dunant 3, 21100 Varese, Italy

Correspondence should be addressed to Carlo Rossetti; carlo.rossetti@uninsubria.it

Received 16 March 2016; Accepted 4 May 2016

Academic Editor: Marisa I. Gómez

Copyright © 2016 Monica Molteni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Toll-like receptor 4 (TLR4) belongs to the family of pattern recognition receptors (PRRs). They are highly conserved receptors that recognize conserved pathogen-associated molecular patterns (PAMPs), thus representing the first line of defense against infections. TLR4 has been long recognized as the sensing receptor for gram-negative lipopolysaccharide (LPS). In addition, it also binds endogenous molecules produced as a result of tissue injury. Hence, TLR4 represents a key receptor on which both infectious and noninfectious stimuli converge to induce a proinflammatory response. TLR4-mediated inflammation, triggered by exogenous or endogenous ligands, is also involved in several acute and chronic diseases, having a pivotal role as amplifier of the inflammatory response. This review focuses on the research progress about the role of TLR4 activation in infectious and noninfectious (e.g., sterile) inflammation and the effects of TLR4 signaling in some pathological conditions.

1. Introduction

The first function described for TLR4 was the recognition of exogenous molecules from pathogens (pathogen-associated molecular pattern molecules (PAMPs)), in particular the molecules from gram-negative bacteria (e.g., LPS) [1]. Recently, it has been widely demonstrated that TLR4 is also involved in the recognition of endogenous molecules released by injured tissues and necrotic cells. These molecules, called damage-associated molecular pattern molecules (DAMPs), induce the activation of a strong proinflammatory response through interaction with TLR4 [2]. Generally, inflammation has a protective role. It is a complex and coordinated process followed by the induction of resolution pathways that restore tissue integrity and function. However, in some cases, excessive and/or poorly regulated inflammatory response can be harmful for the organism. In several diseases with microbial (gram-negative infections) or nonmicrobial etiology (ischemia/reperfusion injury and neurodegenerative and neurological diseases) there is an involvement of TLR4 activation that, under certain circumstances, can contribute to disease progression.

2. TLR4 Signaling

TLR4 is expressed on the cell surface on both hematopoietic and nonhematopoietic cells, including endothelial cells [3], cardiac myocytes [4], and cells of the central nervous system (CNS) [5]. TLR4 is composed of a 608-residue extracellular domain and a 187-residue intracellular domain that is involved in the intracellular signaling cascade [6]. It has been demonstrated that transfection of TLR4 alone is not enough for LPS recognition, and physical association of TLR4 with myeloid differentiation 2 (MD2) on the cell surface is required for ligand-induced activation [7–9]. MD2 lacks transmembrane and intracellular domains and noncovalently associates with the extracellular domain of TLR4 by interaction with LPS, forming the TLR4/MD2 receptor complex [10]. Detailed crystallographic data are reported elsewhere [11–13]. Other accessory molecules that enhance LPS sensing are LPS-binding protein (LBP) and CD14 that favor the transferring of LPS monomers to MD2 and TLR4 [14]. After LPS binding, a dimerization of two TLR4/MD2 complexes occurs, resulting in conformational changes of the TLR4 homodimer that induce the recruitment of adaptor
proteins containing Toll/interleukin-1 receptor-like (TIR) domains. These adaptors associate with the TLR4 cluster through homophilic interactions between TIR domains in the cytoplasmic tail of TLR4 and those present on the adaptors. Four adaptor proteins, involved in two distinct intracellular signaling pathways, have been described: myeloid differentiation primary response protein 88 (MyD88), MyD88-adaptor-like (MAL) protein, also known as TIR domain-containing adaptor protein (TIRAP), TIR domain-containing adaptor inducing IFN-β (TRIF), also known as TIR domain-containing adaptor molecule-1 (TICAM-1), and TRIF-related adaptor molecule (TRAM) [15]. MyD88-mediated signaling occurs mainly at the plasma membrane and involves a rapid recruitment of MyD88 and MAL proteins. Engagement of these adaptor molecules stimulates the recruitment and the activation by phosphorylation of IL-1R-associated kinases (IRAKs), the association of TNF-receptor-associated factor 6 (TRAF6), and the downstream activation of transforming growth factor β-activated kinase 1 (TAK1), mediated by the adaptor proteins, TAK1-binding protein 2 and TAK1-binding protein 3 (TAB2 and TAB3). TAK1 in turn activates the mitogen-activated protein kinases (MAPKs), JUN N-terminal kinase (JNK), p38, extracellular signal-regulated kinases (ERK1/2), and the IkB kinase complex (IKK), leading to the activation of important transcription factors, such as nuclear factor-κB (NF-κB) and activator protein-1 (AP-1), that promote the production of proinflammatory cytokines [15] (Figure 1). Activation of MyD88-independent pathway occurs in the endosomal compartment after internalization of the TLR4-MD2 complex. It involves the recruitment
of adaptor proteins TRIF and TRAM, activation of TNF receptor-associated factor 3 (TRAF3), and the induction of IFN regulatory factor 3 (IRF3) nuclear translocation, mediated by tank-binding kinase 1 (TBK) and IKKε. IRF3 transcription factor promotes the production of type I IFNs (Figure 1). CD14 favors receptor complex internalization [14], even though also CD14-independent translocation of the receptor complex to the endosome and TRIF signaling has been recently demonstrated [16].

Beyond the induction at the transcriptional level of proinflammatory mediators, TLR4 interaction with LPS also orchestrates the induction of mediators such as microRNAs (miRNAs) that posttranscriptionally regulate the shutdown of the proinflammatory response and induce a state of temporary refractoriness to further LPS stimulation. Therefore, a tight regulation of TLR4 signaling is important in tissue homeostasis to avoid excessive inflammation and to induce tissue repair following infection or injury [17, 18].

3. TLR4 Ligands

Since the discovery of the role of TLR4 as a sensor of bacterial LPS by Poltorak et al. [19] and Qureshi et al. [20], several other ligands have been identified from both exogenous sources from both the host tissues and cells (Table 1).

Exogenous ligands (PAMPs) are molecules isolated from bacteria, viruses, fungi, plants, and cyanobacteria. Most are agonists of TLR4/MD2 complex [19–28]. However, from bacteria and cyanobacteria (Rhodobacter and Oscillatoria species, resp.), TLR4 antagonists have also been obtained and their mechanism of action has been well characterized [29, 30]. These antagonists were employed both in vitro and

| Table 1: TLR4 ligands. |
|------------------------|
| TLR4 ligands | Activity | References |
|-----------------|----------|------------|
| **Exogenous natural ligands** | | |
| Lipopolysaccharides from gram-negative bacteria | Agonist | [20] |
| F protein of syncytial virus | Agonist | [21] |
| Mannuronic acid polymers from gram-negative bacteria | Agonist | [22] |
| Teichuronic acid from gram-positive bacteria | Agonist | [23] |
| *Chlamydia pneumoniae* HSP60 | Agonist | [24] |
| *Flavivirus* from *Flavobacterium meningosepticum* | Agonist | [25] |
| Mannan from *S. cerevisiae* and *C. albicans* | Agonist | [26] |
| Dengue virus NS1 protein | Agonist | [27] |
| Plant paclitaxel | Agonist | [28] |
| Lipopolysaccharide from *Rhodobacter* sp. | Antagonist | [29] |
| Lipopolysaccharide-like (CyP) from *Oscillatoria* sp. | Antagonist | [30] |
| **Endogenous ligands** | | |
| **Extracellular matrix ligands** | | |
| Hyaluronan | Agonist | [31] |
| Biglycan | Agonist | [32] |
| Fibronectin | Agonist | [33] |
| Heparan sulphate | Agonist | [34] |
| Tenascin-C | Agonist | [35] |
| **Intracellular and secreted endogenous ligands** | | |
| HMGB1 | Agonist | [36] |
| HSP22 | Agonist | [37] |
| HSP60 | Agonist | [38] |
| HSP70 | Agonist | [39] |
| HSP72 | Agonist | [40] |
| HSP70L1 | Agonist | [41] |
| HSP Gp96 | Agonist | [42] |
| Calcineurin B | Agonist | [43] |
| β-defensin 2 | Agonist | [44] |
| S100 proteins | Agonist | [45] |
| Surfactant protein A | Agonist | [46] |
| Resistin | Agonist | [47] |
| Fibrinogen | Agonist | [48] |
| Amyloid-β | Agonist | [49] |
in vitro in animal models of diseases, allowing investigation of the effects of TLR4 signaling modulation [29, 30].

Endogenous ligands (DAMPs) belong to two main groups: (a) molecules originated from extracellular matrix and [31–35] (b) intracellular mediators passively released or actively secreted by cells [36–49]. Even though for some DAMPs the ability to activate TLR4-mediated signaling has been questioned [50] and the mechanisms of interaction with TLR4/MD2 have not been investigated yet (no crystallographic data are available), there is no doubt that some endogenous molecules could use TLR4 to induce a proinflammatory response. A prototypic molecule of the extracellular matrix that can induce TLR4-mediated inflammation is the glycosaminoglycan hyaluronan. In normal conditions, hyaluronan is present in tissues in a high molecular form (up to $10^6$ Da). After tissue injury, it is degraded into small fragments, which have been shown to activate macrophages via TLR4 both in vitro and in vivo [31, 51]. Endogenous intracellular triggers of TLR4 include the DNA-binding protein high-mobility group box 1 (HMGB1) and cellular heat shock proteins (HSPs). After cell damage and necrosis, these molecules are released in the extracellular milieu, thus inducing a strong proinflammatory response mediated by TLR4 [36, 40, 52]. Beyond its role in sterile inflammation, HMGB1 is also actively released by immunocompetent cells via TLR4 [36, 40, 52].

6. The Role of TLR4 in Infectious Diseases

The central role played by TLR4 in gram-negative infections comes from studies on TLR4-mutated or TLR4-deficient mice [54]. It has been observed that TLR4-mutated strain C3H/HeJ is hyporesponsive to LPS and highly susceptible to infection by gram-negative bacteria such as Salmonella typhimurium and Neisseria meningitidis [54–56]. On the other hand, studies demonstrated that TLR4 $^{-/-}$ mice were protected from endotoxin shock induced by E. coli, thus supporting TLR4 as a possible target for therapeutic intervention in sepsis [57]. In humans, genetic studies on TLR4 polymorphisms (missense mutations D299G and T399I) gave conflicting results. Some studies have linked TLR4 polymorphisms to an increased susceptibility to sepsis due to gram-negative infection; other studies failed to confirm this (reviewed in [58]). Furthermore, results with primary cells isolated from individuals according to D299G/T399I haplotypes did not show any difference in LPS responsiveness [59]. More recent studies have shown a single nucleotide polymorphism rs1536889 in 3’-untranslated region of TLR4 associating with periodontitis [60] and organ failure in sepsis [61]. This polymorphism was shown to affect expression of TLR4 on the cell surface and IL8 production in response to LPS possibly through miRNA regulation [62].

Given the role of TLR4 in the activation of the proinflammatory response during infection, pharmacological approaches targeting TLR4 have been developed with the aim to control host’s deleterious proinflammatory response called “cytokine storm” occurring in the early phase of sepsis. Unfortunately, the results of clinical trials with molecules targeting TLR4 were disappointing [63], suggesting that immune suppression, which follows the “cytokine storm,” represents the leading process in the progression of sepsis [64].

5. The Role of TLR4 in Noninfectious Diseases

5.1. Ischemia/Reperfusion (I/R) Injury. Tissue I/R injury is caused by a sudden interruption of the blood supply to an organ followed by its restoration. Hypoxia induces cell injury and tissue damage with the release of several DAMPs, including HMGB1 [65]. Reperfusion is essential to preserve the organ; however, the exposure of the ischemic area to restored blood flow can lead to an acute inflammatory response causing an additional extensive tissue destruction, a phenomenon termed “reperfusion injury.” DAMPs released by necrotic and distressed cells, through interaction with PRRs, induce the release of proinflammatory mediators by resident macrophages and dendritic cells that recruit, in the reperfusion phase, neutrophils, monocyte, and lymphocytes from blood flow to the ischemic organ. Indeed, the recruitment and activation of neutrophils produce the release of reactive oxygen and nitrogen species and of proteolytic enzymes that are highly cytotoxic and exacerbate tissue damage [66]. Acute myocardial and cerebral infarctions, as well as solid organ transplantations, are all conditions in which I/R injury occurs. In myocardial infarction, reperfusion injury accounts for up to 50% of myocardial infarct size, thus reducing the beneficial effects of reperfusion [67]. In organ transplantation, I/R injury resulting from cold preservation and warm reperfusion of the transplanted graft directly contributes to allograft rejection [68]. Several studies in animal models clearly demonstrated that TLR4, being the target of several DAMPs, plays a key role in I/R injury [69–74]. A great deal of information about the role of TLR4 in I/R injury came from studies using TLR4-mutated (C3H/HeJ) or TLR4 $^{-/-}$ mice. In experimental models of acute myocardial infarction, TLR4 mutant mice showed a reduction of infarct size, decreased activation of NF-$\kappa$B and AP-1, and lower myocardial mRNA levels of interleukin-1$\beta$ (IL-1$\beta$), monocyte chemotactic factor-1 (MCP-1), and interleukin-6 (IL-6), in comparison with wild-type mice [75]. In TLR4 $^{-/-}$ mice we observed reduced infarct sizes and polymorphonuclear cells infiltrating the ischemic area (unpublished observations). The importance of TLR4 was also highlighted by studies of cold I/R injury in syngeneic heart transplant between TLR4 mutant and wild-type mice. The results demonstrated that TLR4 signaling on both donor and recipient cells contributes to systemic and intragraft inflammatory response [76]. Interesting results have also been obtained using a synthetic inhibitor of TLR4/MD2 complex (Eritoran) and a natural cyanobacterial TLR4 antagonist in a murine model of myocardial I/R injury. The results suggest that the
downregulation of TLR4-induced proinflammatory response has beneficial effects in reducing tissue damage [77, 78] and this was associated, in the experiments with the cyanobacterial antagonist, with a reduced number of polymorphonuclear clear leukocytes infiltrating the ischemic area [78]. Confirming results about the positive effects of TLR4 targeting in I/R injury were also obtained in experimental models of hepatic I/R injury in which decreased inflammatory mediators and inhibition of HMGB1 release from hepatocytes were observed after treatment with Eritoran [79]. Indeed, no data are available about the impact of TLR4 signaling inhibition in I/R injury on the long-term tissue repair. Our preliminary data (unpublished results) in a mouse model of acute myocardial infarction using the cyanobacterial TLR4 antagonist suggest that early inhibition of TLR4 signaling just before reperfusion positively affects tissue remodeling, since long-term cardiac function was better in mice treated with the antagonist in comparison to mice treated with vehicle. However, further in-depth studies are needed to clarify the role of TLR4 signaling in tissue repair.

5.2. Neurodegenerative and Neurological Diseases. Neuroinflammation is the common hallmark of several neurodegenerative and neurological diseases [80–82]. In the CNS, microglial cells are resident phagocytes that constantly control the extracellular environment and sense for the presence of pathogens or injured cells. Microglial cells are the immunological “sentinels” of the CNS; they express TLR4 and are highly responsive to LPS in vitro [83]. Microglial activation by noxious stimuli represents a defensive response with the aim to restore tissue homeostasis. In several pathological conditions, however, persistent exposure to danger signals can cause aberrant microglia activation with the production of proinflammatory mediators and the release of reactive oxygen and nitrogen species that result in neuronal dysfunction and/or neuronal cell loss. It has been reported that direct TLR4 stimulation with LPS produces immediate and long-term memory deficits in mice models of endotoxemia, especially in aged mice [84, 85]. In similar experiments, the contribution of HMGB1 on memory impairment mediated by both TLR4 and receptor for advanced glycation end products (RAGE) has been demonstrated [85, 86]. Increased expression of TLR4 in microglial cells has been observed in animal models and patients of Alzheimer’s disease (AD) [87–89], Parkinson’s disease (PD) [90], and Amyotrophic Lateral Sclerosis (ALS) [91, 92].

In AD, amyloid-β (Aβ) oligomers directly induce microglial activation through several receptors, including TLR4 [49, 80]. Activated microglia has an active role not only in the production of proinflammatory mediators but also in the phagocytosis of Aβ. Indeed, the continuous formation of Aβ caused, at least in part, by positive feedback between inflammation and amyloid precursor protein processing drives a chronic detrimental and nonresolving proinflammatory loop. In this context, the role of TLR4 is not clear, probably due to the complex mechanisms controlling reacting microglia phenotypes [80, 93]. In vitro studies showed a role of TLR4 in the Aβ-induced neurotoxicity [87, 88]. Differently, some experimental studies using transgenic AD mice carrying mutated TLR4 showed reduced microglial activation but also reduced Aβ clearance with exacerbation of cognitive deficits [94]. These data suggest that there is a delicate balance between the production of proinflammatory mediators and Aβ phagocytosis in glial cells, and an inefficient clearance of Aβ, only partially TLR4-dependent, could be involved in disease progression [80, 93, 95, 96].

In support of this hypothesis, Michaud et al. [97] recently demonstrated that treatment of transgenic AD mice with monophosphoryl lipid A (MPLA), a LPS-derived analog of gram-negative lipid A, led to a significant reduction of Aβ accumulation in the brain and enhanced cognitive function. MPLA is a TLR4 agonist but does not induce large amounts of proinflammatory mediators. In this context, MPLA was shown to induce a potent phagocytic response by microglia while triggering a moderate inflammatory response in vivo.

In PD, where accumulation of extracellular misfolded α-synuclein is observed, contrasting results about the role of TLR4 have been obtained. In a mouse model of PD induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), TLR4 was shown to mediate cell death of dopaminergic neurons and TLR4-deficient mice were partially protected against MPTP toxicity [98]. Indeed, experimental TLR4 deficiency was shown to decrease α-synuclein clearance in vitro by murine microglia [99, 100].

The studies about the role of TLR4 in other neurodegenerative and neurological diseases, ALS and epilepsy, gave more clear results. In ALS upregulation of TLR4 and cytoplasmic HMGB1 were observed in reactive glia (astrocytes and microglia) and neurons of the spinal cord in ALS patients [91]. In a mouse genetic model of ALS (superoxide dismutase 1-mutant mice), chronic administration of LPS (once every 2 weeks for 3 months) in presymptomatic mice accelerated motor neuron degeneration and disease progression [101]. Furthermore, De Paola et al. [92] demonstrated that the chronic treatment with a TLR4 antagonist in a mouse model of spontaneous motor neuron degeneration (wobbler mice) produced potent anti-inflammatory effects (reduction of glialosis and TNF-α production) with significant improvements of motor functional tests. In epilepsy, analyses of hippocampal specimens obtained at surgery from patients with drug-resistant temporal lobe epilepsy showed increased TLR4 and HMGB1 expression in glial cells (astrocytes) and neurons [102]. Moreover, in acute and chronic mice models of seizures a proconvulsant pathway involving TLR4-HMGB1 axis was demonstrated. Intriguingly, antagonists targeting TLR4 were shown to delay seizure onset and decrease acute and chronic seizure recurrence [102].

6. Conclusions

Since its discovery, a great deal of experimental data supported TLR4 as a key player of the inflammatory process due to both infectious and noninfectious stimuli. In several pathological conditions TLR4 engagement contributes to disease resolution; however, when TLR4 activation pathways are poorly regulated, it can contribute to disease progression. More information is needed to clarify the role of TLR4 engagement in the different phases of I/R injury or during the
The authors declare that there are no competing interests regarding the publication of this paper.

Competing Interests

The effect of TLR4 signaling on the fine phenotypic changes regarding neurodegenerative processes, with a particular attention to the development of molecules acting on TLR4 could represent new disease-modifying therapeutic agents for the treatment of I/R injury or for neurodegenerative diseases.

References

[1] S. Akira and K. Takeda, “Toll-like receptor signaling,” Nature Reviews Immunology, vol. 4, no. 7, pp. 1–16, 2004.
[2] L. Yu, L. Wang, and S. Chen, “Endogenous toll-like receptor ligands and their biological significance,” Journal of Cell. and Molecular Medicine, vol. 14, no. 11, pp. 2592–2603, 2010.
[3] K. R. Taylor, J. M. Trowbridge, J. A. Rudisill, C. C. Termeer, J. C. Simon, and R. L. Gallo, “Hyaluronan fragments stimulate endothelial recognition of injury through TLR4,” The Journal of Biological Chemistry, vol. 279, no. 17, pp. 17079–17084, 2004.
[4] S. Frantz, L. Kobzik, Y.-D. Kim et al., “Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium,” The Journal of Clinical Investigation, vol. 104, no. 3, pp. 271–280, 1999.
[5] T. Kielian, “Toll-like receptors in CNS glial inflammation and homeostasis,” Journal of Neuroscience Research, vol. 83, no. 5, pp. 711–730, 2006.
[6] R. Medzhitov, P. Preston-Hurlburt, and C. A. Janeway Jr., “A human homologue of the Drosophila toll protein signals activation of adaptive immunity,” Nature, vol. 388, no. 6640, pp. 394–397, 1997.
[7] Y. Nagai, S. Akashi, M. Nagafuku et al., “Essential role of MD-2 in LPS responsiveness and TLR4 distribution,” Nature Immunology, vol. 3, no. 7, pp. 667–672, 2002.
[8] A. B. Schromm, E. Lien, P. Hennke et al., “Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling,” The Journal of Experimental Medicine, vol. 194, no. 1, pp. 79–88, 2001.
[9] R. Shimazu, S. Akashi, H. Ogata et al., “MD-2, a molecule that confers lipopolysaccharide responsiveness on toll-like receptor 4,” Journal of Experimental Medicine, vol. 189, no. 11, pp. 1777–1782, 1999.
[10] S. Viriyakosol, P. S. Tobias, R. L. Kitchens, and T. N. Kirkland, “MD-2 binds to bacterial lipopolysaccharide,” The Journal of Biological Chemistry, vol. 276, no. 41, pp. 38044–38051, 2001.
[11] H. M. Kim, B. S. Park, J.-I. Kim et al., “Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist eritoran,” Cell, vol. 130, no. 5, pp. 906–917, 2007.
[12] B. S. Park, D. H. Song, H. M. Kim, B.-S. Choi, H. Lee, and J.-O. Lee, “The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex,” Nature, vol. 458, no. 7242, pp. 1191–1195, 2009.
[13] U. Ohito, K. Fukase, K. Miyake, and T. Shimizu, “Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 19, pp. 7421–7426, 2012.
[14] I. Zanoni, R. Ostuni, L. R. Marek et al., “CD14 controls the LPS-induced endocytosis of toll-like receptor 4,” Cell, vol. 147, no. 4, pp. 868–880, 2011.
[15] G. M. Barton and R. Medzhitov, “Toll-like receptor signaling pathways,” Science, vol. 300, no. 5625, pp. 1524–1525, 2003.
[16] R. Rajaiah, D. J. Perkins, D. D. C. Ireland, and S. N. Vogel, “CD14 dependence of TLR4 endotoxins and TRIF signaling displays ligand specificity and is dissociable in endotoxin tolerance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 27, pp. 8391–8396, 2015.
[17] M. A. Nahid, K. M. Pauley, M. Satoh, and E. K. L. Chan, “miR-146a is critical for endotoxin-induced tolerance: implication in innate immunity,” The Journal of Biological Chemistry, vol. 284, no. 50, pp. 34590–34599, 2009.
[18] L. A. O’Neill, F. J. Sheedy, and C. E. McCoy, “MicroRNAs: the fine-tuners of Toll-like receptor signalling,” Nature Reviews Immunology, vol. 11, no. 3, pp. 163–175, 2011.
[19] A. Poltorak, X. He, I. Smirnova et al., “Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene,” Science, vol. 282, no. 5396, pp. 2085–2088, 1998.
[20] S. T. Qureshi, L. Larivi`ere, G. Leveque et al., “Endotoxin-tolerant mice have mutations in toll-like receptor 4 (Tlr4),” Journal of Experimental Medicine, vol. 189, no. 4, pp. 615–625, 1999.
[21] E. A. Kurt-Jones, L. Popova, L. Kwinn et al., “Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus,” Nature Immunology, vol. 1, no. 5, pp. 398–401, 2000.
[22] T. H. Flo, L. Ryan, E. Latz et al., “Involvement of Toll-like receptor (TLR) 2 and TLR4 in cell activation by mannuronic acid polymers,” The Journal of Biological Chemistry, vol. 277, no. 38, pp. 35489–35495, 2002.
[23] S. Yang, S. Sugawara, T. Monodane et al., “Micrococcus luteus teichuronic acids activate human and murine monocyte cells in a CD14- and toll-like receptor 4-dependent manner,” Infection and Immunity, vol. 69, no. 4, pp. 2025–2030, 2001.
[24] P. Rallabhandi, J. Bell, M. S. Boukhvalova et al., “Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling,” The Journal of Immunology, vol. 177, no. 1, pp. 322–332, 2006.
[25] K. Gomi, K. Kawasaki, Y. Kawai, M. Shiozaki, and M. Nishijima, “Toll-like receptor 4-MD-2 complex mediates the signal transduction induced by flavolipin, an amino acid-containing lipid unique to Flavobacterium meningosepticum,” The Journal of Immunology, vol. 168, no. 6, pp. 2939–2943, 2002.
[26] L. Romani, “Immunity to fungal infections,” Nature Reviews Immunology, vol. 11, no. 4, pp. 275–288, 2011.
[27] J. K. Koh, D. S. Lee, D. A. Muller et al., “Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity,” Science Translational Medicine, vol. 7, no. 304, Article ID 304ra142, 2015.
[28] K. Kasasaki, S. Akasi, R. Shimazu, T. Yoshida, K. Miyake, and M. Nishijima, “Mouse toll-like receptor 4-MD-2 complex mediates lipopolysaccharide—mimetic signal transduction by Taxol,” The Journal of Biological Chemistry, vol. 275, no. 4, pp. 2251–2254, 2000.
[29] G. D. Kutuzova, R. M. Albrecht, C. M. Erickson, and N. Qureshi, “Diphosphoryl lipid A from Rhodobacter sphaeroides blocks the
M. A. Chase, D. S. Wheeler, K. M. Lierl, V. S. Hughes, H. R. R. M. Vabulas, S. Braedel, N. Hilf et al., "The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via toll-like receptor 4," *The Journal of Experimental Medicine*, vol. 205, no. 6, pp. 1481–1492, 2006.

C. Termeer, F. Benedix, J. Sleeman et al., "Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4," *The Journal of Experimental Medicine*, vol. 195, no. 1, pp. 99–111, 2002.

L. Schaefer, A. Babelova, E. Kiss et al., "The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages," *The Journal of Clinical Investigation*, vol. 115, no. 8, pp. 2223–2233, 2005.

S. P. Gondokaryono, H. Ushio, F. Niyonsaba et al., "The extra domain A of fibronectin stimulates murine mast cells via toll-like receptor 4," *Journal of Leukocyte Biology*, vol. 82, no. 3, pp. 657–665, 2007.

G. B. Johnson, G. J. Brunn, Y. Kodaira, and J. L. Platt, "Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by toll-like receptor 4," *Journal of Immunology*, vol. 168, no. 10, pp. 5233–5239, 2002.

K. Midwood, S. Sacre, A. M. Piccinini et al., "Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease," *Nature Medicine*, vol. 15, no. 7, pp. 774–780, 2009.

M. T. Lotze and K. J. Tracey, "High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal," *Nature Reviews Immunology*, vol. 5, no. 4, pp. 331–342, 2005.

M. F. Roelofs, W. C. Boelens, L. A. B. Joosten et al., "Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis," *Journal of Immunology*, vol. 176, no. 11, pp. 7021–7027, 2006.

K. Ohashi, V. Burkart, S. Flohé, and H. Kolb, "Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex," *The Journal of Immunology*, vol. 164, no. 2, pp. 558–561, 2000.

A. Asea, M. Rehli, E. Kabiungo et al., "Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4," *Journal of Biological Chemistry*, vol. 277, no. 17, pp. 15028–15034, 2002.

M. A. Chase, D. S. Wheeler, K. M. Lierl, V. S. Hughes, H. R. Wong, and K. Page, "Hsp72 induces inflammation and regulates cytokine production in airway epithelium through a TLR4- and NF-κB-dependent mechanism," *The Journal of Immunology*, vol. 179, no. 9, pp. 6318–6324, 2007.

H. Fang, Y. Wu, X. Huang et al., "Toll-like receptor 4 (TLR4) is essential for Hsp70-like protein 1 (HSP70LI) to activate dendritic cells and induce Th1 response," *The Journal of Biological Chemistry*, vol. 286, no. 35, pp. 30393–30400, 2011.

R. M. Vabulas, S. Braedel, N. Hilf et al., "The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the toll-like receptor 2/4 pathway," *Journal of Biological Chemistry*, vol. 277, no. 23, pp. 20847–20853, 2002.

W. Wu, Q. Chen, F. Geng et al., "Calcineurin B stimulates cytokine production through a CD14-independent Toll-like receptor 4 pathway," *Immunology and Cell Biology*, vol. 94, no. 3, pp. 285–292, 2015.
[59] B. Ferwerda, M. B. B. McCall, K. Verheijen et al., "Functional consequences of toll-like receptor 4 polymorphisms," *Molecular Medicine*, vol. 14, no. 5-6, pp. 346–352, 2008.

[60] T. Fukusaki, N. Ohara, Y. Hara, A. Yoshimura, and K. Yoshiura, "Evidence for association between a Toll-like receptor 4 gene polymorphism and moderate/severe periodontitis in the Japanese population," *Journal of Periodontal Research*, vol. 42, no. 6, pp. 541–545, 2007.

[61] A. Mansur, L. von Gruben, A. F. Popov et al., "The regulatory toll-like receptor 4 genetic polymorphism rs1136889 is associated with renal, coagulation and hepatic organ failure in sepsis patients," *Journal of Translational Medicine*, vol. 12, no. 1, pp. 177–185, 2014.

[62] K. Sato, A. Yoshimura, T. Kaneko et al., "A single nucleotide polymorphism in 3′-untranslated region contributes to the regulation of toll-like receptor 4 translation," *Journal of Biological Chemistry*, vol. 287, no. 30, pp. 25163–25172, 2012.

[63] S. M. Opal, P. F. Laterre, B. Francois et al., "Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial," *Journal of the American Medical Association*, vol. 309, no. 11, pp. 1154–1162, 2013.

[64] N. A. Hutchins, J. Unsinger, R. S. Hotchkiss, and A. Ayala, "The new normal: immunomodulatory agents against sepsis immune suppression," *Trends in Molecular Medicine*, vol. 20, no. 4, pp. 224–233, 2014.

[65] M. Andrassy, H. C. Volz, J. C. Igwe et al., "High-mobility group box-1 in ischemia-reperfusion injury of the heart," *Circulation*, vol. 117, no. 25, pp. 3216–3226, 2008.

[66] R. F. van Golen, T. M. van Gulik, and M. Heger, "The sterile immune response during hepatic ischemia/reperfusion," *Cytokine and Growth Factor Reviews*, vol. 23, no. 3, pp. 69–84, 2012.

[67] D. M. Yellon and D. J. Hausenloy, "Myocardial reperfusion injury," *The New England Journal of Medicine*, vol. 357, no. 11, pp. 1074–1135, 2007.

[68] J. Howell, P. Gow, P. Angus, and K. Visvanathan, "Role of toll-like receptors in liver transplantation," *Liver Transplantation*, vol. 20, no. 3, pp. 270–280, 2014.

[69] J.-I. Oyama, C. Blais Jr., X. Liu et al., "Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice," *Circulation*, vol. 109, no. 6, pp. 784–798, 2004.

[70] D. J. Kaczorowski, A. Nakao, R. Vallabhaneni et al., "Mechanisms of toll-like receptor 4 (TLR4)-mediated inflammation after cold ischemia/reperfusion in the heart," *Transplantation*, vol. 87, no. 10, pp. 1455–1463, 2009.

[71] A. Tsung, R. Sahai, H. Tanaka et al., "The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion," *Journal of Experimental Medicine*, vol. 201, no. 7, pp. 1133–1134, 2005.

[72] J. R. Caso, J. M. Pradillo, O. Hurtado, P. Lorenzo, M. A. Moro, and I. Lizasoain, "Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke," *Circulation*, vol. 115, no. 12, pp. 1599–1608, 2007.

[73] H. Wu, G. Chen, K. R. Wyburn et al., "TLR4 activation mediates kidney ischemia/reperfusion injury," *Journal of Clinical Investigation*, vol. 117, no. 10, pp. 2847–2859, 2007.

[74] F. Hua, J. Ma, T. Ha et al., "Activation of Toll-like receptor 4 signaling contributes to hippocampal neuronal death following global cerebral ischemia/reperfusion," *Journal of Neuroimmunology*, vol. 190, no. 1-2, pp. 101–111, 2007.

[75] A. J. Chong, A. Shimamoto, C. R. Hampton et al., "Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart," *The Journal of Thoracic and Cardiovascular Surgery*, vol. 128, no. 2, pp. 170–179, 2004.

[76] D. J. Kaczorowski, A. Nakao, K. P. Mollen et al., "Toll-like receptor 4 mediates the early inflammatory response after cold ischemia/reperfusion," *Transplantation*, vol. 84, no. 10, pp. 1279–1287, 2007.

[77] A. Shimamoto, A. J. Chong, C. R. Hampton et al., "Inhibition of toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury," *Circulation*, vol. 114, no. 1, pp. 1270–1274, 2006.

[78] A. Soldo, M. Molteni, C. Rossetti et al., "CyP, a toll-like receptor 4 antagonist, protects the heart from ischemia/reperfusion injury," *European Heart Journal*, vol. 32, supplement 1, p. 690, 2011.

[79] K. A. Mcdonald, H. Huang, S. Tohme et al., "Toll-like receptor 4 antagonist eritoran tetrasodium attenuates liver ischemia and reperfusion injury through inhibition of high-mobility group box protein B1 (HMGB1) signaling," *Molecular Medicine*, vol. 20, pp. 639–648, 2015.

[80] M. T. Heneka, M. J. Carson, J. E. Khoury et al., "Neuroinflammation in Alzheimer’s disease," *The Lancet Neurology*, vol. 14, no. 4, pp. 388–405, 2015.

[81] A. Vezzani, "Epilepsy and inflammation in the brain: overview and pathophysiology," *Epilepsy Currents*, vol. 14, no. 1, pp. 3–7, 2014.

[82] T. C. Frank-Cannon, L. T. Alto, F. E. McAlpine, and M. G. Tansey, "Does neuroinflammation fan the flame in neurodegenerative diseases?" *Molecular Neurodegeneration*, vol. 4, no. 1, pp. 47–60, 2009.

[83] J. K. Olson and S. D. Miller, "Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs," *The Journal of Immunology*, vol. 173, no. 6, pp. 3916–3924, 2004.

[84] A. J. Tarr, K. A. McLinden, D. Kranjac, R. A. Kohman, W. Amaral, and G. W. Boehm, "The effects of age on lipopolysaccharide-induced cognitive deficits and interleukin-1β expression," *Behavioural Brain Research*, vol. 217, no. 2, pp. 481–485, 2011.

[85] N. Terrando, A. R. Fidalgo, M. Vizcaychipi et al., "The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction," *Critical Care*, vol. 14, article R88, 2010.

[86] A. Mazarati, M. Maroso, V. Iori, A. Vezzani, and M. Carli, "High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and receptor for advanced glycation end products," *Experimental Neurology*, vol. 232, no. 2, pp. 143–148, 2011.

[87] S.-C. Tang, J. D. Lathia, P. K. Selvaraj et al., "Toll-like receptor 4 mediates neuronal apoptosis induced by amyloid β-peptide and the membrane lipid peroxidation product 4-hydroxynonenal," *Experimental Neurology*, vol. 213, no. 1, pp. 114–121, 2008.

[88] S. Walter, M. Letiembre, Y. Liu et al., "Inhibition of toll-like receptor 4-mediated IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction," *Critical Care*, vol. 14, article R88, 2010.

[89] S. Frank, E. Copanaki, G. J. Burbach, U. C. Müller, and T. Deller, "Differential regulation of toll-like receptor mRNAs in amyloid plaque-associated brain tissue of aged APP23 transgenic mice," *Neuroscience Letters*, vol. 453, no. 1, pp. 41–44, 2009.
[90] M. A. Panaro, D. D. Lofrumento, C. Saponaro et al., “Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of Parkinson's-like disease,” *Immunopharmacology and Immunotoxicology*, vol. 30, no. 4, pp. 729–740, 2008.

[91] M. Casula, A. M. Iyer, W. G. M. Spliet et al., “Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue,” *Neuroscience*, vol. 179, pp. 233–243, 2011.

[92] M. De Paola, A. Mariani, P. Bigini et al., “Neuroprotective effects of toll-like receptor 4 antagonism in spinal cord cultures and in a mouse model of motor neuron degeneration,” *Molecular Medicine*, vol. 18, no. 6, pp. 971–981, 2012.

[93] M. R. Minter, J. M. Taylor, and P. J. Crack, “The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease,” *Journal of Neurochemistry*, vol. 136, no. 3, pp. 457–474, 2016.

[94] M. Song, J. Jin, J.-E. Lim et al., “TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease,” *Journal of Neuroinflammation*, vol. 8, pp. 92–106, 2011.

[95] K. G. Mawuenyega, W. Sigurdson, V. Ovod et al., “Decreased clearance of CNS β-amyloid in Alzheimer's disease,” *Science*, vol. 330, no. 6012, pp. 1774–1776, 2010.

[96] S. E. Hickman, E. K. Allison, and J. El Khoury, “Microglial dysfunction and defective β-amyloid clearance pathways in aging alzheimer's disease mice,” *Journal of Neuroscience*, vol. 28, no. 33, pp. 8354–8360, 2008.

[97] J.-P. Michaud, M. Hallé, A. Lampron et al., “Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 110, no. 5, pp. 1941–1946, 2013.

[98] C. Noelker, L. Morel, T. Lescot et al., “Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease,” *Scientific Reports*, vol. 3, article 1393, 2013.

[99] N. Stefanova, L. Fellner, M. Reindl, E. Masliah, W. Poewe, and G. K. Wenning, “Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons,” *American Journal of Pathology*, vol. 179, no. 2, pp. 954–963, 2011.

[100] L. Fellner, R. Irschick, K. Schanda et al., “Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia,” *Glia*, vol. 61, no. 3, pp. 349–360, 2013.

[101] M. D. Nguyen, T. D'Aigle, G. Gowing, J.-P. Julien, and S. Rivest, “Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis,” *The Journal of Neuroscience*, vol. 24, no. 6, pp. 1340–1349, 2004.

[102] M. Maroso, S. Balosso, T. Ravizza et al., “Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures,” *Nature Medicine*, vol. 16, no. 4, pp. 413–419, 2010.